The Comparative Study on Rh-Endostatin (Endostar) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.

Trial Profile

The Comparative Study on Rh-Endostatin (Endostar) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs Endostatin (Primary) ; Cisplatin; Gemcitabine
  • Indications Lung cancer
  • Focus Therapeutic Use
  • Sponsors Simcere Pharmaceutical Group
  • Most Recent Events

    • 10 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top